CA1146858A - Blood substitute containing modified hemoglobin - Google Patents

Blood substitute containing modified hemoglobin

Info

Publication number
CA1146858A
CA1146858A CA000356067A CA356067A CA1146858A CA 1146858 A CA1146858 A CA 1146858A CA 000356067 A CA000356067 A CA 000356067A CA 356067 A CA356067 A CA 356067A CA 1146858 A CA1146858 A CA 1146858A
Authority
CA
Canada
Prior art keywords
hemoglobin
glycol
process according
polyalkylene
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000356067A
Other languages
French (fr)
Inventor
Yuji Iwashita
Katsumi Ajisaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of CA1146858A publication Critical patent/CA1146858A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

ABSTRACT OF THE DISCLOSURE

A novel modified hemoglobin comprises hemoglobin coupled with a polyalkylene glycol or its derivative, and is useful as a blood substitute; the oxygen-carrying capa-city of this hemoglobin is nearly equal to that of native hemoglobin, and the residence time in the circulation is satisfactorily long.

Description

~1468S~

This invention relates to a novel blood substitute containing a modified hemoglobin as an oxygen-carrying material.
A blood substitute containing haemoglobin or hemoglobin free from stromal components as an oxygen-carrying material is well known ~S.F. Rabiner et al. J. Ex. Med., vol. 126, p 1142(1967)). On the other hand, it is also known that when the hemoglobin is infused into the circu-lation, it is rapidly excreted through the kidneys and metabolized by other metabolic routes. In order to solve this problem, various proposals have been made, for example, a hemoglobin cross-linked with glutaraldehyde, (Japanese Published Patent Application 76-63920 KOKAI), a hemoglobin coupled with dextran (Japanese Published Patent Application 77-51016 KOKAI), and a hemoglobin combined with hydroxyethyl starch (German Offenlegungsschrift 2616086). The first case has the disadvantage that oxygen is difficult to transfer at the tissue, because the oxygen affinity of the hemoglobin is too tight. In the latter two cases, high concentration of the hemoglobin often leads to an unfavourable result because of its high viscosity.
It has now been found that when hemoglobin is com-bined with a polyalkylene glycol or its derivative (herein-after referred to as "modified hemoglobin"), the oxygen-carrying ability of the modified hemoglobin is nearly equal to that of the original or native hemoglobin, and the resi-dence time in the circulation is satisfactorily long.
Thus in accordance with the invention there is provided a modified hemoglobin comprising hemoglobin coupled with a polyalkylene glycol or a derivative thereof.
In another aspect of the invention there is provided ~146858 a process of producing a modified hemoglobin which comprises coupling hemoglobin with a polyalkylene glycol or a deriva-tive thereof.
The alkylene glycol of the polyalkylene glycol may suitably contain 2 to 6 and preferably 2 to 4 carbon atoms.
The polyalkylene glycol and its derivatives, which may be used in the invention include polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, an ether of one of the above-mentioned polyalkylene glycols and an alcohol having 1 to 16 carbon atoms, for example monomethyl ether, monocetyl ether and monooleyl ether, an ester of one of the above polyalkylene glycols and a carboxylic acid containing 2 to 18 carbon atoms, for example, monobutyl ester and monostearyl ester, and a dehydrated product of one of the above polyalkylene glycols and an amine having 1 to 18 carbon atoms, for example, propylamine and stearylamine. The above polyalky-lene glycols and their derivatives are hereinafter referred to as the "polymer employed in the invention". The molecular weight of the polymer employed in the invention is suitably 300 to 20,000, and preferably 750 to 5,000 for elongation of the residence time in the blood circulation.
The hemoglobin employed in the invention may be, for example, human, cow, swine, sheep, horse, dog, monkey, rabbit or hen hemoglobin.
The hemoglobin and the polymer employed in the invention may be coupled by conventional techniques for example, they are directly combined using a condensing agent, for example, cyanogen bromide, or they are combined using a cross-linking reagent, for example, cyanuric chloride,
2,2'-dichlorobenzidine, p,p'-difluoro-m,m'-dinitrodiphenyl-114685~

sulfone and 2,4-dichloronitrobenzene. It is appropriate to combine 4 to 120 molecules of the polymer employed in the invention with one hemoglobin molecule.
The modified hemoglobin may be prepared according to the following methods:
(1) Polyethylene glycol is reacted with 2 to 5 moles, preferably 3 moles of cyanogen bromide at a pH of 9 to 10.
Residual cyanogen bromide is removed from the reaction mixture for example by gel filtration or dialysis, and the resulting product is reacted with 1/10-1/500 moles, prefera-bly 1/50-1/100 moles of hemoglobin at a pH of 7 to 9, pre-ferably 7.5 to 8 in an aqueous solution;
(2) Polyethylene glycol is added to benzene containing an excess amount of sodium carbonate, and is reacted with 2 to 5 moles, preferably 3 to 4 moles of cyanuric chloride.
The reaction product of polyethylene glycol-4,6-dichloro-S-triazine is then separated, and 1 mole thereof is reacted with 1 to 1/500 moles, preferably 1/10 to 1/100 moles of hemoglobin in a buffer solution at a pH of 8 to 9.5.
The above methods are also applicable to other polymers employed in the invention.
The invention is illustrated by reference to the accompanying drawings, in which, FIGURE 1 is a visible spectrum of a modified hemoglobin of the invention, and FIGURE 2 is a 13C N.M.R. spectrum of a modified hemoglobin of the invention.
The modified hemoglobin of the invention is readily soluble in water, and the colour of the solution is red. A
visible spectrum of a modified hemoglobin of the invention consisting of human hemoglobin and polyethylene glycol of which the molecular weight is about 4000, is shown in Figure 1 and 3C nuclear magnetic resonance spectrum of a modified hemoglobin of the invention consisting of human hemoglobin and methoxy polyethylene glycol of which the molecular weight is about 750 is shown in Figure 2.
me modified hemoglobin is a nontoxic material, and the reason is that the modified hemoglobin is a combined matter of hemoglobin separated from a living body, and the polymers employed in the invention are highly non-toxic.
Since oxygen affinity of the modified hemoglobin is nearly equal to or slightly stronger than that of natural hemoglobin, the modified hemoglobin is preferable for carrying oxygen to the tissues. Furthermore, the residence time of the modi-fied hemoglobin in the ciculation is about 2 to 4 times longer than that of stroma-free hemoglobin itself. As de~cribed above, the modified hemoglobin is a material as a blood substitute. In particular, it is known that a protein modi-fied by polyethylene glycol loses the antigenicity of the protein (A. Abuchowski et al., J. Biol. Chem., vol. 25~, p 3582 (1977)), and accordingly, there is no fear that the modified hemoglobin will act as antigen in the body.
me number of polyalkylene glycol units attached to hemoglobin described in the Examples was determined as follows:
The concentration (Co) of a modified hemoglobin solution was determined by the cyanomethemoglobin method, and the weight of the modified hemoglobin (Mo) was measured after freeze-drying of vOml of the solution. Thus, the number of polyaklylene glycol units (N) is:

mO -cOvO
M
N =
cOVo where Ml and M2 are the molecular weights of polyalkylene glycol and hemoglobin, respectively.
The invention is illustrated in particular embodi-ments in the following examples:
Example 1 2.5 Grams (0.003 mole) of polyethylene glycol mono-methyl ether of which the mean molecular weight is 750 were dissolved in 40ml water, and lg (0.0095 mole) of cyanogen bromide which was previously dissolved in 5ml dioxane was added dropwise to the aqueous solution while the solution was chilled in an ice bath. Then, the mixture was stirred for one hour, while the mixture was maintained in the range of pH 9 to 10 using 2N NaOH. The mixture was adjusted to p~ 7.5 using lN HCl and concentrated to 20 ml by ultra-filtration using a G-05T* membrane (made by Bioengineering Co., Ltd.) of which the cut-off molecular weight is 500 dalton. The concentrate was diluted with 300ml of phosphate buffer solution of pH 7.5, and then concentrated to 20ml by the ultrafiltration again. 20ml of a 10% aqueous solution of human hemoglobin were added to the concentrate while the concentrated solution was stirred and chilled in an ice bath.
The reaction mixture was then allowed to stand overnight at 4C. Subsequently, the reaction mixture was passed through a column where CM-Sephadex** gel was packed and pre-equili-brated to pH 6Ø The column was eluted with O.OSM phosphate buffer solution of pH 6.8 and the fractions of the modified hemoglobin were collected. The fractions were desalted and concentrated by ultrafiltration using a A-15T* membrane of which the cut-off molecular weight is 15000 dalton. The concentrate was filtered through a 0.45~ membrane, and the filtrate contained 3.5g of a combined material of hemoglobin * supplier's designation ** trade mark ~1468~8 and polyethylene glycol monomethyl ether as a dried matter.
About 10 molecules of polyethylene glycol monomethyl ether were combined with one hemoglobin molecule.

Example 2 7.2 Grams (0.01 mole) of polyethylene glycol mono-methyl ether of which the mean molecular weight is 750 were dissolved in 500 ml benzene, and lOg of sodium carbonate were added to the solution. 5.5 Grams (0.03 mole) of cyanuric chloride was added to the solution while it was cooled in an ice bath and vigorously stirred. The reaction mixture was vigorously stirred overnight at room temperature. The pre-cipitate was filtered off, and 1~ of petroleum ether (b.p.
30-70C) was added to the filtxate. A precipitate of 2-0-methoxypolyethyleneglycol-4,6-dichloro-S-triazine (activated polyethylene glycol) was separated, and washed with petro-leum ether. The dry amount of the activited polyethylene glycol was 11.5g. 0.5 Gram (O.0077mmo1.) of hemoglobin were dissolved in lOOml of borate buffer solution of pH 9.2, and 1.7 grams (1.8 mmol.) of the dry activated polyethylene glycol were added to the solution while it was cooled in an ice bath. The mixture was stirred for one hour in an ice bath, and ultrafiltration using a PM-30* membrane (made by Amicon Co.) was repeated twice, and thereby the remaining hemoglobin and activated polyethylene glycol were removed. The residue contained 2.1g of the modified hemoglobin as a dried matter.
About 50 molecules of polyethylene glycol monomethyl ether were combined with one hemoglobin molecule.

ExamPle 3 19 Grams (0.01 mole) of polyethylene glycol mono-methyl ether of which the mean molecular weight is 1,900 were * supplier's designation 114685l~

activated using 400 ml of benzene, lOg of sodium carbonate and 5.5g (0.03 mole) of cyanuric chloride in the same manner as employed in Example 2, and accordingly, 24g of the acti-vated polyethylene glycol were obtained. 6.4 Grams (3.1 mmol.) of the activated polyethylene glycol so produced were treated with 2g (0.031 mmol.) of hemoglobin and 200ml of borate buffer solution of pH 9.2 in the same manner as Example 2, and 5.6g of the modified hemoglobin were obtained.
About 57 molecules of polyethylene glycol monomethyl ether were combined with one hemoglobin molecule.

ExamPle 4 50 Grams (0.01 mole) of polyethylene gylcol mono-methyl ether of which the mean molecular weight is 5,000 were activated using 500 ml of benzene, lOg of sodium carbonate and 5.5g (0.03 mole) of cyanuric chloride in the same manner as Example 2, and accordingly, 53g of the activated poly-ethylene glycol were obtained. 40 Grams of the activated polyethylene glycol so produced were treated with 20 ml of 10% hemoglobin solution and 450 ml of borate buffer solution of pH 9.2 in the same manner as Example 2, and 14 g of the modified hemoglobin were obtained. About 75 molecules of polyethylene glycol monomethyl ether were combined with one hemoglobin molecule.

Example 5 40 Grams (0.002 mole~ of polyethylene glycol of which the mean molecular weight is 20,000 were mixed with 1 of benzene, lOg of sodium carbonate and l lg (0.006 mole) of cyanuric chloride, and the mixture was stirred overnight at room temperature. 1 Litre of petroleum ether was added to the mixture, and the precipitate formed was treated in the same manner as in Example 2 ts obtain 39g of activated poly-~1461~5~

ethylene glycol. 10 Grams (0.0005 mole) of the above activa-ted polyethylene glycol were added to the mixture of 20 ml (0.00003 mole) of 10% hemoglobin and 400 ml of borate buffer solution of pH 9.2 which was previously cooled in an ice bath, and then stirred for one hour. The reaction mixture was concentrated by ultrafiltration using XM-100* membrane (made by Amicon Co.) and the modified hemoglobin in the reaction mixture was adsorbed on a column of CM-Sephadex**
gel which was pre-equilibrated with 0.05M phosphate buffer solution of pH 6Ø The first fraction of elution using pH
6.3 phosphate buffer solution, was discarded, and the next fraction using pH 6.8 phosphate buffer solution was collected.
The fraction was concentrated by using the XM-100* membrane, and 3g of the modified hemoglobin were obtained as a dried matter. About 4 molecules of polyethylene glycol were com-bined with one hemoglobin molecule.

Example 6 Using 12.5g (0.005 mole) of polyethylene glycol monostearyl ester of which the mean molecular weight is 2,500, 400 ml of benzene, 5g of sodium carbonate and 2.75g (0.015 mole) of cyanuric chloride, the same treatment as Example 2 was carried out, and accordingly 13.5g of activated polyethyl-ene glycol were obtained. 10.5 Grams 10.004 mole) of the above activated polyethylene glycol were treated with 25 ml (0.04 mmol.) of 10h hemoglobin solution and 900 ml of borate buffer solution of pH 9.2 in the same manner as Example 2, and 8g of the modified hemoglobin were obtained. About 52 molecules of polyethylene glycol monostearyl ester were combined with one hemoglobin molecule.

* supplier's designation ** trade mark Example 7 Using 5g (0.005 mole) of polyethylene glycol mono-oleyl ether of which the mean molecular weight is 1,000, 400 ml of benzene, 5g of sodium carbonate and 2.75g (0.015 mole) of cyanuric chloride, the same treatment as Example 2 was carried out, and accordingly 6g of activated polyethylene glycol were obtained. 5.3 Grams (0.002 mole) of the above activated polyethylene glycol were treated with 1.3g (0.02 mmol.) of bovineihemoglobin (made by Sigma Co.) and 450ml borate buffer solution of pH 9.2 in the same manner as Example 2, and 4.2 g of the modified hemoglobin were obtained.
About 85 molecules of polyethylene glycol monooleyl ether were combined with one hemoglobin molecule.

Example 8 12 Grams (0.003 mole) of polypropylene glycol of which the mean molecular weight is 4,000 were dissolved in 120 ml water. Using 0.0095 mole of cyanogen bromide, the solution was treated in the same manner as Example 1, and accordingly a concentrate of ultrafiltration was obtained.
Using 2 g of porcine hemoglobin (made by Sigma Co.), the concentrate was treated in the same manner as Example 1, and accordingly 7 g of the modified hemoglobin were obtained.
About 15 molecules of polypropylene glycol were combined with one hemoglobin molecule.

Experiment The residence time in the blood vessels and the oxygen affinity of the modified hemoglobins were measured.

Two rats having an average weight of 350 g were employed as samples. The rats were injected with 5 ml of 4 to 6% modified hemoglobin per kg of body weight of rat through a femoral vein, and 0.5 ml portions of blood were ~i46858 withdrawn at 5, 10, 15, 30, 60, 90 and 120 minutes after the injection. Each blood sample was centrifuged, and the concentration of the modified hemoglobin in the plasma was determined by the cyanomethemoglobin spectral method. The data were plotted on a graph, and the half-life residence time of the injected modified hemoglobin in the plasma was determined from the graph.
The results are tabulated in Table 1 below.

Table 1 Hemoglobin Half-Life residence time The modified hemoglobin 150 minutes of Example 1 The material " 120 "
. of the invention of Example 2 " 110 of Example 3 .- 210 "
of Example 4 Control Natural hemoglobin 50 Polyhemoglobin of Japanese Patent 100 "
Publication No. 76-63920 . .

As to the modified hemoglobin solution (O.lM NaCl solution, pH 7.40), the oxygen partial pressure at which the hemoglobin is half saturated with oxygen (P50-value) was determined from an oxygen dissociation curve which was pro-duced using a Hem-O-Scan* apparatus made by Amicon Co. The data are shown in Table 2.

,0 * trade mark Table 2 , Hemoglobin P50 .
The modified hemoglobin13.5 mmHg of Example 2 " 15.0 The material of Example 3 of the invention .. 19.5 of Example 5 Natural hemoglobin 15.0 Polyhemoglobin of Control Japanese Patent Publication 9.0 No. 76-63920 Dextran-Hemoglobin of Japanese Patent 10.0 Publication No. 77-51016 _

Claims (21)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A process of producing a modified hemoglobin which comprises coupling hemoglobin with a polymer having a molecular weight of 300 to 20,000, said polymer being a polyalkylene glycol or a derivative thereof.
2. A process according to claim 1, wherein said hemoglobin is coupled with a polyalkylene glycol selected from the group consisting of polyethylene glycol, poly-propylene glycol and a copolymer of ethylene glycol and propylene glycol.
3. A process according to claim 1, wherein said hemoglobin is coupled with a derivative of a polyalkylene glycol selected from the group consisting of ethers, esters and a dehydrated product of a polyalkylene and an amine.
4. A process according to claim 1, wherein said hemoglobin is combined with a polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene gly-col, an ether of one of said glycols and an alcohol having 1 to 16 carbon atoms, an ester of one of said glycols and a carboxylic acid having 2 to 18 carbon atoms, and a dehydrated product of one of said glycols and an amine having 1 to 18 carbon atoms.
5. A process according to claim 1, wherein said hemoglobin is human, cow, swine, sheep, horse, dog, monkey, rabbit or hen hemoglobin.
6. A process according to claim 2, 3 or 4, wherein said hemoglobin is human, cow, swine, sheep, horse, dog, monkey, rabbit or hen hemoglobin.
7. A process according to claim 1 or 4, wherein said polymer has a molecular weight of 750 to 5,000.
8. A process according to claim 2, wherein said polyalkylene glycol has a molecular weight of 750 to 5,000.
9. A process according to claim 3, wherein said derivative has a molecular weight of 750 to 5,000.
10. A process according to claim 1, 2 or 4, wherein said coupling is carried out with cyanogen bromide.
11. A process according to claim 1, 2 or 4, wherein said coupling is carried out with a cross-linking agent.
12. A process according to claim 1, wherein said hemoglobin and said polymer are attached to each other directly.
13. A process according to claim 1, wherein the alkylene glycol of said polyalkylene glycol contains 2 to 6 carbon atoms.
14. A modified hemoglobin comprising hemoglobin coupled with a polymer having a molecular weight of 300 to 20,000, said polymer being a polyalkylene glycol or a derivative thereof, whenever prepared by the process of claim 1, or by an obvious chemical equivalent.
15. A modified hemoglobin as defined in claim 14, wherein the alkylene glycol of said polyalkylene glycol contains 2 to 6 carbon atoms, whenever prepared by the process of claim 13, or by an obvious chemical equivalent.
16. A modified hemoglobin, as defined in claim 14, wherein said hemoglobin is coupled with a polyalkylene glycol selected from the group consisting of polyethylene glycol, polypropylene glycol and a copolymer of ethylene glycol and propylene glycol, whenever prepared by the process of claim 2, or by an obvious chemical equivalent.
17. A modified hemoglobin, as defined in claim 14, wherein said hemoglobin is coupled with a derivative of a polyalkylene glycol selected from the group consisting of ethers, esters and a dehydrated product of a polyalkylene and an amine, whenever prepared by the process of claim 3, or by an obvious chemical equivalent.
18. A modified hemoglobin wherein the hemoglobin is combined with a polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, an ether of one of said glycols and an alcohol having 1 to 16 carbon atoms, an ester of one of said glycols and a carboxylic acid having 2 to 18 carbon atoms, and a dehydrated product of one of said glycols and an amine having 1 to 18 carbon atoms, whenever prepared by the process of claim 4, or by an obvious chemical equivalent.
19. A modified hemoglobin, as defined in claim 14, wherein said hemoglobin is human, cow, swine, sheep, horse, dog, monkey, rabbit or hen hemoglobin, whenever prepared by the process of claim 5, or by an obvious chemical equivalent.
20. A modified hemoglobin, as defined in claim 14, wherein said hemoglobin is coupled with a polyalkylene glycol selected from the group consisting of polyethylene glycol, polypropylene glycol and a copolymer of ethylene glycol and propylene glycol, whenever prepared by the process of claim 2, or by an obvious chemical equivalent.
21. A modified hemoglobin, as defined in claim 14, wherein said hemoglobin is coupled with a derivative of a polyalkylene glycol selected from the group consisting of ethers, esters and a dehydrated product of a polyalkylene and an amine, and has a molecular weight of 750 to 5,000, whenever prepared by the process of claim 3, or by an obvious chemical equivalent.
CA000356067A 1979-07-11 1980-07-11 Blood substitute containing modified hemoglobin Expired CA1146858A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP54087910A JPS6023084B2 (en) 1979-07-11 1979-07-11 blood substitute
JP87910/1979 1979-07-11

Publications (1)

Publication Number Publication Date
CA1146858A true CA1146858A (en) 1983-05-24

Family

ID=13928063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000356067A Expired CA1146858A (en) 1979-07-11 1980-07-11 Blood substitute containing modified hemoglobin

Country Status (6)

Country Link
US (1) US4301144A (en)
JP (1) JPS6023084B2 (en)
CA (1) CA1146858A (en)
DE (1) DE3026398A1 (en)
FR (1) FR2460674A1 (en)
GB (1) GB2055868B (en)

Families Citing this family (845)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
JPS58225025A (en) * 1982-06-24 1983-12-27 Nippon Chem Res Kk Long active composition
JPS5959629A (en) * 1982-09-27 1984-04-05 Nippon Chem Res Kk Sustained release composition
JPS59104323A (en) * 1982-12-07 1984-06-16 Ajinomoto Co Inc Blood substitute
DE3340592A1 (en) * 1983-11-10 1985-05-23 B. Braun Melsungen Ag, 3508 Melsungen CONJUGATES OF MACROMOLECULAR COMPOUNDS TO HAEMOGLOBINE, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THE SAME
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
USRE34271E (en) * 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPS6153223A (en) * 1984-08-22 1986-03-17 Ajinomoto Co Inc Preparation of bonded compound of hemoglobin and polyalkylene glycol
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5239061A (en) * 1990-06-20 1993-08-24 Research Corporation Technologies, Inc. Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
ATE168014T1 (en) * 1991-11-08 1998-07-15 Somatogen Inc HEMOGLOBINS AS A DRUG DELIVERY SYSTEM
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CZ288926B6 (en) * 1994-03-31 2001-09-12 Amgen Inc. MGDF derivative, process of its preparation and pharmaceutical preparation in it is comprised
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US6306454B1 (en) * 1994-10-17 2001-10-23 Baxter International Inc. Method for producing improved medical devices and devices so produced
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
NZ310778A (en) 1995-06-07 1999-10-28 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor
US5865784A (en) * 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
EP1704878B1 (en) 1995-12-18 2013-04-10 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
EP1500702A1 (en) * 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
WO1998033924A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
DE69831248T2 (en) 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland METHOD AND COMPOSITIONS FOR OPTIMIZING OXYGEN TRANSPORT IN CELL-FREE SYSTEMS
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
WO1999010484A1 (en) * 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740738B2 (en) 1997-04-07 2001-11-15 Genentech Inc. Humanized antibodies and methods for forming humanized antibodies
TR199903123T2 (en) 1997-04-07 2000-05-22 Genentech, Inc. Anti-Vegf antikorlar�.
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DK0981618T4 (en) * 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2 antibody
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
EP1659131B1 (en) 1997-09-17 2009-11-04 Genentech, Inc. Polypeptides and nucleic acids encoding the same
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
ES2306480T3 (en) 1997-09-18 2008-11-01 Genentech, Inc. DCR3 POLYPEPTIDE, A TNFR HOMOLOGIST.
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
ES2316173T3 (en) 1997-10-29 2009-04-01 Genentech, Inc. INDUCIBLE GENES BY WNT-1.
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
DE69840105D1 (en) 1997-11-21 2008-11-20 Genentech Inc PLATE-SPECIFIC ANTIGENES AND THEIR PHARMACEUTICAL USE
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69939732D1 (en) 1998-01-15 2008-11-27 Genentech Inc APO-2 LIGAND
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
IL138488A0 (en) 1998-03-17 2001-10-31 Genentech Inc Polypeptides homologous to vegf and bmp1
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ES2292242T5 (en) 1998-05-15 2011-05-04 Genentech, Inc. THERAPEUTIC USES OF IL-17 HOMOLOGICAL POLYPEPTIDES.
PT1086138E (en) * 1998-06-12 2010-01-04 Genentech Inc Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
KR100719202B1 (en) 1998-10-23 2007-05-16 키린-암젠 인코포레이티드 A COMPOUND BINDING TO MPl RECEPTOR AND A PHARMACEUTICAL COMPOSITION THEREOF
SI1135498T1 (en) 1998-11-18 2008-06-30 Genentech Inc Antibody variants with higher binding affinity compared to parent antibodies
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
JP2000230000A (en) * 1999-02-08 2000-08-22 Hokkaido Univ Nitrogen monoxide metabolite-polyoxyalkylene- hemoglobin conjugate combination
CA2266174A1 (en) * 1999-03-18 2000-09-18 Hemosol Inc. Hemoglobin-antioxidant conjugates
KR100316154B1 (en) * 1999-03-26 2001-12-12 노광 Polyethylene glycol-hemoglobin conjugate
EP1171595A1 (en) 1999-04-12 2002-01-16 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6602501B1 (en) 1999-08-12 2003-08-05 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP2003202B1 (en) 1999-10-05 2011-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6180598B1 (en) 1999-10-07 2001-01-30 Deanna J. Nelson Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
DK1897945T3 (en) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologous polypeptides and therapeutic uses thereof.
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE10031744A1 (en) 2000-06-29 2002-01-17 Sanguibio Tech Ag Mammalian hemoglobins compatible with blood plasma, crosslinked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, their production and their use
DE10031740A1 (en) 2000-06-29 2002-02-14 Sanguibio Tech Ag Artificial oxygen carriers from cross-linked modified human or pig hemoglobin with improved properties, processes for their technically simple production from purified material in high yields, and their use
FR2811323B1 (en) * 2000-07-07 2006-10-06 Fuma Tech Gmbh HYBRID MATERIAL, USE OF SAID HYBRID MATERIAL, AND METHOD OF MANUFACTURING THE SAME
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PT1313850E (en) 2000-08-28 2008-11-18 Agensys Inc Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20030077590A1 (en) * 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US6576452B1 (en) * 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US20030232334A1 (en) * 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002077263A2 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
KR20040080940A (en) 2001-05-14 2004-09-20 덴드레온 코포레이션 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
MXPA03011985A (en) 2001-06-20 2004-03-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
AU2002320628A1 (en) 2001-07-19 2003-03-03 Albert Einstein College Of Medecine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols
CN1636067A (en) * 2001-08-03 2005-07-06 杰南技术公司 TACIs and BR3 polypeptides and uses thereof
WO2003020892A2 (en) 2001-08-29 2003-03-13 Genentech, Inc. Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
ES2390531T3 (en) 2001-09-18 2012-11-13 Genentech, Inc. Compositions and procedures for the diagnosis and treatment of tumor
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2003050276A1 (en) * 2001-12-05 2003-06-19 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc Compositions and methods for the treatment of immune related diseases
EP1485477B1 (en) 2002-02-25 2009-05-13 Genentech, Inc. Novel type-1 cytokine receptor glm-r
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
KR100508358B1 (en) * 2002-03-20 2005-08-17 주식회사 바이오폴리메드 Preparation of G-CSF stoichiometrically conjugated with biocompatible polymers at cystein residue
EP2093233A1 (en) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
BR0308710A (en) * 2002-03-26 2007-01-09 Biosynexus Inc antimicrobial polymer conjugates
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) * 2002-06-07 2007-08-08 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
JP3912206B2 (en) * 2002-07-05 2007-05-09 株式会社日立製作所 Fuel pump for in-cylinder direct fuel injection system
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1692127A (en) * 2002-07-25 2005-11-02 健泰科生物技术公司 TACI antibodies and uses thereof
CN101792749B (en) * 2002-08-12 2012-09-05 金克克国际有限公司 Mutant colibacillus appa phytase enzymes
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
ES2781475T3 (en) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Methods to increase the production of hematopoietic stem cells and platelets
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
JP2011516026A (en) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
JP2006508163A (en) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins referred to as 24P4C12 useful in the treatment and detection of cancer
AU2002364944A1 (en) * 2002-12-12 2004-07-09 Baxter International Inc. Method for producing medical devices and devices so produced
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
JP2006516548A (en) * 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
AU2004204942A1 (en) * 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
EP2343315A3 (en) 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
MXPA05009743A (en) 2003-03-12 2006-03-09 Genentech Inc Use of bv8 and/or eg-vegf to promote hematopoiesis.
NZ542306A (en) 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
US7235639B2 (en) * 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
ATE541052T1 (en) 2003-05-30 2012-01-15 Agensys Inc VARIANTS OF PROSTATE STEM CELL ANTIGEN (PSCA) AND PARTIAL SEQUENCES THEREOF
RU2005136988A (en) 2003-05-30 2006-06-10 Дженентек, Инк. (Us) ANTIBODY TREATMENT AGAINST VEGF
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CA2526402A1 (en) * 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
KR100835786B1 (en) 2003-07-08 2008-06-09 제넨테크, 인크. - il-17a/f heterologous polypeptides and therapeutic uses thereof
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
EP1648998B1 (en) 2003-07-18 2014-10-01 Amgen Inc. Specific binding agents to hepatocyte growth factor
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
AR045614A1 (en) * 2003-09-10 2005-11-02 Hoffmann La Roche ANTIBODIES AGAINST THE RECEIVER OF INTERLEUQUINA- 1 AND USES OF THE SAME
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
US20070274988A1 (en) * 2003-10-10 2007-11-29 Five Prime Therapeautics, Inc. Kiaa0779, Splice Variants Thereof, and Methods of Their Use
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP4901478B2 (en) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド Compositions and methods for the treatment of tumors of hematopoietic origin
PT2311873T (en) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc M-csf-specific monoclonal antibody and uses thereof
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
NZ550964A (en) 2004-04-28 2011-05-27 Angiodevice Internat Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2008500338A (en) * 2004-05-25 2008-01-10 イコス・コーポレイション Method for treating and / or preventing abnormal proliferation of hematopoietic cells
EP2583981A3 (en) 2004-05-28 2013-07-31 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1796602A4 (en) 2004-09-17 2016-10-19 Angiotech Pharm Inc Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
JP5091679B2 (en) 2004-10-15 2012-12-05 アメリカ合衆国 Multi-domain amphiphilic helix peptides and methods of use thereof
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
DE602005022928D1 (en) 2004-11-30 2010-09-23 Abgenix Inc ANTIBODIES AGAINST GPNMB AND ITS USES
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP1885356A2 (en) * 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2008535853A (en) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Cancer-related genes
CA2604885A1 (en) 2005-04-07 2006-10-19 Guoying Yu Cacna1e in cancer diagnosis, detection and treatment
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
TWI299257B (en) * 2005-05-16 2008-08-01 Tung Hai Biotechnology Corp γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
PL1912675T3 (en) 2005-07-25 2014-10-31 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1913028B1 (en) * 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
JP5457671B2 (en) * 2005-07-28 2014-04-02 ノバルティス アーゲー M-CSF specific monoclonal antibody and use thereof
CN101257926A (en) * 2005-08-04 2008-09-03 尼克塔治疗亚拉巴马公司 Conjugates of a G-CSF moiety and a polymer
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8105585B2 (en) * 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
US8691944B2 (en) * 2005-10-04 2014-04-08 The Research Foundation For The State University Of New York Fibronectin polypeptides and methods of use
US20090155850A1 (en) * 2005-10-28 2009-06-18 The Florida International University Board Of Trustees Horse:Human Chimeric Antibodies
WO2007056858A1 (en) 2005-11-18 2007-05-24 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
RU2473565C2 (en) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPβ), AND USE THEREOF
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9506056B2 (en) 2006-06-08 2016-11-29 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
MX363905B (en) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Single-chain multivalent binding proteins with effector function.
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
CN101626783A (en) * 2006-08-04 2010-01-13 诺华有限公司 EPHB3-specific antibody and its application
EP3415532A1 (en) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
BRPI0717512A2 (en) 2006-09-29 2013-11-19 Hoffmann La Roche CCR5 ANTIBODIES AND USES OF THE SAME
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
AU2007329759B2 (en) 2006-10-27 2013-05-30 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
JP5732182B2 (en) 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． Compositions and methods for treating eye diseases and symptoms
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
JP5313909B2 (en) * 2006-11-13 2013-10-09 アイコス コーポレイション Thienopyrimidinone for the treatment of inflammatory diseases and cancer
NZ576272A (en) 2006-11-14 2012-01-12 Genentech Inc Modulators of neuronal regeneration
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
CN101199856B (en) * 2006-12-15 2011-04-20 天津协和生物科技发展有限公司 Oxygen-carrying anti-shock medicament
US7943728B2 (en) 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
EP2125013A4 (en) * 2007-01-26 2010-04-07 Bioinvent Int Ab Dll4 signaling inhibitors and uses thereof
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
TW201307390A (en) 2007-02-02 2013-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
US8415453B2 (en) * 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
US8088887B2 (en) * 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
KR101508397B1 (en) 2007-02-22 2015-04-08 제넨테크, 인크. Methods for detecting inflammatory bowel disease
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
JP5989299B2 (en) 2007-05-30 2016-09-07 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． Compositions and methods for lysophosphatidic acid binding
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
US9845355B2 (en) 2007-07-16 2017-12-19 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
PL2474557T3 (en) 2007-07-16 2015-02-27 Genentech Inc Anti-CD79b antibodies and immunoconjugates and methods of use
EP2489730B1 (en) 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
JP2010535788A (en) * 2007-08-09 2010-11-25 シントニックス・ファーマシューティカルズ・インコーポレーテッド Immunomodulatory peptides
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
ES2672769T3 (en) * 2007-08-29 2018-06-18 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
EP2231181B1 (en) 2007-12-17 2016-02-17 Marfl AB New vaccine for the treatment of mycobacterium related disorders
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
JP5701064B2 (en) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド Ferroportin antibody and method of use thereof
RU2553566C2 (en) 2008-01-31 2015-06-20 Дженентек, Инк. ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM
ES2618292T3 (en) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Antibodies against and use of human CD39 to inhibit the activity of regulatory T cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
CN104655854A (en) 2008-04-09 2015-05-27 健泰科生物技术公司 Novel compositions and methods for the treatment of immune related diseases
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2724415C (en) 2008-05-15 2016-09-13 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
JP2011526916A (en) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosus
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
CN102282172B (en) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
KR20190064664A (en) 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD86 Antagonist Multi-Target Binding Proteins
US8481033B2 (en) 2008-10-07 2013-07-09 INSERM (Institute National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
KR20110081862A (en) 2008-10-22 2011-07-14 제넨테크, 인크. Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AU2009312532B2 (en) * 2008-11-06 2013-05-16 Ichnos Sciences SA Treatment with anti-alpha2 integrin antibodies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (en) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 Therapies for hematologic malignancies
DK2365803T3 (en) 2008-11-24 2018-01-22 Univ Northwestern POLYVALENT RNA NANOPARTICLE COMPOSITIONS
KR101977846B1 (en) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi inhibitors and methods of use
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
JP2012521197A (en) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Carrier immunoglobulin and use thereof
EA019499B1 (en) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8124740B2 (en) 2009-03-25 2012-02-28 Genentech, Inc. Anti- α5 β1 antibodies and uses thereof
CA2752908A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
NZ595574A (en) 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
AR076541A1 (en) 2009-05-05 2011-06-22 Amgen Inc MUTANTS OF FGF21 AND USES OF THE SAME
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
JP6166041B2 (en) 2009-06-15 2017-07-19 バレリオン セラピューティクス， エルエルシー Methods and compositions for treating tubule myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptide
JP2012530493A (en) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド Chimeric polypeptides and uses thereof
KR20120097481A (en) * 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 POLYPEPTIDES SELECTIVE FOR alpha;v beta;3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN(HSA) AND PHARMACEUTICAL USES THEREOF
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011045704A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CN102656266B (en) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 There is the chimeric fibroblast growth factor of the receptor-specific of change
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MX2012004638A (en) 2009-10-22 2012-07-04 Genentech Inc Modulation of axon degeneration.
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
AU2010313154B2 (en) 2009-10-30 2016-05-12 Northwestern University Templated nanoconjugates
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
RU2012124093A (en) 2009-11-12 2013-12-20 Дженентек, Инк. METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
PE20121584A1 (en) 2009-11-30 2012-11-29 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) * 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2512600A2 (en) 2009-12-18 2012-10-24 Amgen Inc. Wise binding agents and epitopes
KR20140130751A (en) 2009-12-22 2014-11-11 로슈 글리카트 아게 Anti-her3 antibodies and uses thereof
JP5739908B2 (en) 2009-12-23 2015-06-24 國立成功大學Ｎａｔｉｏｎａｌ Ｃｈｅｎｇ Ｋｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ Compositions and methods for the treatment of angiogenesis-related eye diseases
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CN105693861A (en) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 Heterodimer binding protein and application thereof
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
AU2011218294A1 (en) 2010-02-16 2012-08-30 Medimmune, Llc HSA-related compositions and methods of use
KR20130004579A (en) 2010-02-23 2013-01-11 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
EP3590966A1 (en) 2010-02-23 2020-01-08 Sanofi Anti-alpha2 integrin antibodies and their uses
CN102859364A (en) 2010-02-25 2013-01-02 桑格特公司 Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CN106432474A (en) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 CTLA4 proteins and their uses
CN103025345B (en) 2010-03-19 2016-01-20 巴克斯特国际公司 TFPI inhibitor and using method
MY187990A (en) 2010-03-31 2021-11-07 Boehringer Ingelheim Int Anti-cd40 antibodies
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CN107090045A (en) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 Composition and method for tumor diagnosis and therapy
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP2571516B1 (en) 2010-05-18 2017-11-15 Neumedicines, Inc Il-12 formulations for enhancing hematopoiesis
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
JP2013530187A (en) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Compositions and methods for treating inflammatory diseases.
AR082163A1 (en) 2010-07-15 2012-11-14 Hoffmann La Roche SPECIFICALLY BINDING ANTIBODIES OF THE HUMAN TSLPR AND METHODS OF USING THEMSELVES
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN105198981B (en) 2010-08-20 2019-07-16 惠氏有限责任公司 Osteogenic protein through designing
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
US9445990B2 (en) 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
EP3214442A1 (en) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
US8778346B2 (en) 2010-11-04 2014-07-15 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP3222635A1 (en) 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
AR085911A1 (en) 2011-03-16 2013-11-06 Sanofi Sa SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION
EP2691419B1 (en) 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
ES2724801T3 (en) 2011-04-19 2019-09-16 Pfizer Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment
MY168757A (en) 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
WO2012158964A2 (en) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals for osteoporosis
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
KR101969515B1 (en) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 Treatment of coagulation disease by administration of recombinant vwf
EP2718456B1 (en) 2011-06-13 2019-04-24 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
US9045526B2 (en) 2011-06-23 2015-06-02 The Regents Of The University Of Michigan Compound and method for modulating opioid receptor activity
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP2744828A4 (en) 2011-08-16 2014-12-31 Univ Emory Jaml specific binding agents, antibodies, and uses related thereto
RU2014109985A (en) 2011-08-17 2015-09-27 Дженентек, Инк. INHIBITION OF ANGIOGENESIS IN REFRACTOR TUMORS
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US8987422B2 (en) 2011-09-22 2015-03-24 Amgen Inc. CD27L antigen binding proteins
UY34347A (en) 2011-09-26 2013-04-30 Novartis Ag DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
DK2766392T3 (en) 2011-10-10 2019-10-07 Xencor Inc PROCEDURE FOR CLEANING ANTIBODIES
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2766044B1 (en) 2011-10-13 2019-12-11 Aerpio Therapeutics, Inc. Treatment of ocular disease
JP2015504038A (en) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Fibronectin binding domain with reduced immunogenicity
AU2012339734B2 (en) 2011-11-16 2017-02-16 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
RU2014124530A (en) 2011-11-23 2015-12-27 Идженика, Инк. ANTIBODIES TO CD98 AND WAYS OF THEIR APPLICATION
US20150045301A1 (en) 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2804620A4 (en) 2012-01-18 2016-04-13 Neumedicines Inc Il-12 for radiation protection and radiation-induced toxicity mitigation
KR102052983B1 (en) 2012-01-26 2019-12-06 크리스토퍼 제이. 소레스 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
EP2830663B1 (en) 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
AU2013256724A1 (en) 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
UY34813A (en) 2012-05-18 2013-11-29 Amgen Inc ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
CA3175758A1 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
KR20150030706A (en) 2012-06-11 2015-03-20 암젠 인코퍼레이티드 Dual receptor antagonistic antigen-binding proteins and uses thereof
CN105050618B (en) 2012-06-21 2018-11-16 索伦托治疗有限公司 Antigen-binding proteins in conjunction with c-Met
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
DK3431497T3 (en) 2012-06-27 2022-10-10 Univ Princeton Cleaved INTEINS, CONJUGATES AND USES THEREOF
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
RS60318B1 (en) 2012-08-01 2020-07-31 Ikaika Therapeutics Llc Mitigating tissue damage and fibrosis via anti-ltbp4 antibody
EP3613765A1 (en) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
ES2684552T3 (en) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies directed against ICOS to treat graft versus host disease
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
TWI660972B (en) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 Anti-mcam antibodies and associated methods of use
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US11065304B2 (en) 2012-11-20 2021-07-20 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
PT2922875T (en) 2012-11-20 2017-05-31 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
DK3444281T3 (en) 2012-11-20 2022-02-07 Eumederis Pharmaceuticals Inc IMPROVED PEPTID MEDICINES
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR102561553B1 (en) 2013-03-15 2023-07-31 젠코어 인코포레이티드 Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
PE20151673A1 (en) 2013-03-15 2015-11-27 Genentech Inc IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
HUE045859T2 (en) 2013-03-15 2020-01-28 Amgen Res Munich Gmbh Single chain binding molecules comprising n-terminal abp
CN105263514B (en) 2013-03-15 2019-04-26 本质生命科学有限公司 Anti- hepcidin antibody and application thereof
WO2014144911A2 (en) 2013-03-15 2014-09-18 Capon Daniel J Hybrid immunoglobulin containing non-peptidyl linkage
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
LT2981822T (en) 2013-05-06 2020-12-28 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
MX351127B (en) 2013-05-30 2017-10-03 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins.
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
JP6267792B2 (en) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド Methods for treating homozygous familial hypercholesterolemia
AR097648A1 (en) 2013-09-13 2016-04-06 Amgen Inc COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP6419796B2 (en) 2013-10-04 2018-11-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antibodies that specifically bind to HER3
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
WO2015057583A1 (en) 2013-10-14 2015-04-23 The United States Of America, As Represented By The Secretary Treatment of chronic kidney disease with sahps
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
EP3733868A3 (en) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergen detection
ES2759252T3 (en) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Nuclease-albumin fusions and therapeutic methods
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
ES2752552T3 (en) 2013-12-20 2020-04-06 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3094646B1 (en) 2014-01-13 2020-04-15 Valerion Therapeutics, LLC Internalizing moieties
DK3097122T3 (en) 2014-01-24 2020-08-10 Ngm Biopharmaceuticals Inc ANTIBODIES BINDING BETA-KLOTHO DOMAIN 2 AND METHODS OF USING IT
EP3099715B1 (en) 2014-01-31 2020-11-18 Boehringer Ingelheim International GmbH Novel anti-baff antibodies
KR102472816B1 (en) 2014-02-20 2022-11-30 알러간, 인코포레이티드 Complement component c5 antibodies
BR112016019825A2 (en) 2014-02-27 2017-10-17 Allergan Inc complement factor bb antibodies
CA2941697A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for modifying the immune response
LT3701971T (en) 2014-03-14 2023-01-10 Biomolecular Holdings Llc Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
WO2015158851A1 (en) 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma ANTI-HER4 HUMAN ANTIBODY
BR112016027595B1 (en) 2014-05-28 2023-12-26 Mederis Diabetes, Llc PEPTIDE PRODUCT, PHARMACEUTICAL COMPOSITION AND ITS USES
ES2905777T3 (en) 2014-05-30 2022-04-12 Shanghai Henlius Biotech Inc Anti-epidermal growth factor receptor (EGFR) antibodies
BR112016029076B1 (en) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc POLYPEPTIDE AND COMPOSITION COMPRISING THE SAME FOR INHIBITING CLEAVAGE OF C5 IN A CELLULAR SYSTEM
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN114057857A (en) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 CHAGASIN-based scaffold compositions, methods and uses
AR101400A1 (en) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody constructs
US9765145B2 (en) 2014-08-22 2017-09-19 Sorrento Therapeutics, Inc. Fully human anti-C-X-C chemokine receptor 3 (CXCR5) antibodies
EP3575316A1 (en) 2014-08-27 2019-12-04 Amgen, Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015335029B2 (en) 2014-10-24 2021-09-23 Astrazeneca Ab Combination
HUE061672T2 (en) 2014-11-12 2023-08-28 Seagen Inc Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (en) 2014-11-26 2022-05-11 Xencor Inc HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
CN111018987B (en) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 Antibody capable of specifically binding to human endothelin receptor and application thereof
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
ES2881484T3 (en) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anti-PD-1 antibodies
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
SI3240801T1 (en) 2014-12-31 2021-04-30 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
RS60916B1 (en) 2015-01-23 2020-11-30 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
SI3250230T1 (en) 2015-01-28 2022-01-31 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
AU2016219170B2 (en) 2015-02-13 2021-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CTLA4
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN113527495A (en) 2015-04-08 2021-10-22 索伦托药业有限公司 Antibody therapeutics that bind to CD38
UA126270C2 (en) 2015-04-10 2022-09-14 Емджен Інк. Interleukin-2 muteins for the expansion of t-regulatory cells
CN116063541A (en) 2015-04-17 2023-05-05 安进研发（慕尼黑）股份有限公司 Bispecific antibody constructs for CDH3 and CD3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3307253A4 (en) 2015-06-12 2018-11-21 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
WO2017020001A2 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
CA2992788A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
US20170058038A1 (en) 2015-09-01 2017-03-02 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of lupus nephritis
TWI799366B (en) 2015-09-15 2023-04-21 美商建南德克公司 Cystine knot scaffold platform
JP7002446B2 (en) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー CD3 binding polypeptide
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
WO2017059371A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
EP3359575B1 (en) 2015-10-09 2020-07-22 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CN116217729A (en) 2015-11-12 2023-06-06 思进公司 Glycan interaction compounds and methods of use
BR112018011270A2 (en) 2015-12-04 2018-11-21 Univ California isolated antibody, pharmaceutical composition, and methods for treating or reducing the recurrence rate of a cancer in a patient and for detecting cancer stem cells.
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
KR20190026642A (en) 2016-01-29 2019-03-13 소렌토 쎄라퓨틱스, 인코포레이티드 The antigen-binding protein that binds to PD-L1
DK3411402T3 (en) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
WO2017156032A1 (en) 2016-03-07 2017-09-14 Charlestonpharma, Llc Anti-nucleolin antibodies
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
JP7422480B2 (en) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation
TWI826351B (en) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 R antibodies, their pharmaceutical compositions and uses
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
CN117330747A (en) 2016-07-15 2024-01-02 武田药品工业株式会社 Methods and materials for assessing response to plasmacytoid and plasma cell depleting therapies
TWI790206B (en) 2016-07-18 2023-01-21 法商賽諾菲公司 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
CN110198729A (en) 2016-09-09 2019-09-03 豪夫迈·罗氏有限公司 The selective inhibitor peptides of frizzled protein
BR112019005129A2 (en) 2016-09-16 2019-06-04 Shanghai Henlius Biotech Inc anti-pd-1 antibodies
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
WO2018067754A1 (en) 2016-10-04 2018-04-12 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
US11548935B2 (en) 2016-10-14 2023-01-10 Neomatrix Therapeutics Inc. Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
JP7142630B2 (en) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド IL15/IL15Rα heterodimeric FC-fusion protein
TW202300515A (en) 2016-10-20 2023-01-01 法商賽諾菲公司 Anti-chikv antibodies and uses thereof
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018089305A1 (en) 2016-11-08 2018-05-17 University Of Miami Anti-secretogranin iii (scg3) antibodies and uses thereof
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CN110087668A (en) 2016-12-07 2019-08-02 Ra制药公司 The regulator of complement activity
CA3043333A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. Glycan-interacting compounds and methods of use
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
MX2019010848A (en) 2017-03-16 2019-10-30 Innate Pharma Compositions and methods for treating cancer.
EP3601350A1 (en) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
UY37726A (en) 2017-05-05 2018-11-30 Amgen Inc PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
EP3648787A1 (en) 2017-07-07 2020-05-13 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
KR20200037235A (en) 2017-07-07 2020-04-08 박스알타 인코퍼레이티드 Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
CN111094334A (en) 2017-07-19 2020-05-01 美国卫生与公众服务部 Antibodies and methods for diagnosis and treatment of hepatitis B virus infection
MX2020002070A (en) 2017-08-22 2020-03-24 Sanabio Llc Soluble interferon receptors and uses thereof.
WO2019070086A2 (en) * 2017-09-20 2019-04-11 RIM, Chang Ho Oxygen carrying blood substitute obtained from swine blood and the manufacturing method thereof
CN111295395A (en) 2017-11-02 2020-06-16 牛津生物治疗公司 Antibodies and methods of use
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018369639A1 (en) 2017-11-14 2020-04-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
US11440957B2 (en) 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
CN111818971A (en) 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 Improved peptide drugs for the treatment of NASH and other disorders
RU2020127792A (en) 2018-01-26 2022-02-28 Дженентек, Инк. IL-22-Fc fusion proteins AND METHODS OF APPLICATION
LT3743088T (en) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc compositions and methods of use
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
AU2019222705A1 (en) 2018-02-14 2020-10-01 Horizon Therapeutics Ireland Dac Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
RU2020128013A (en) 2018-03-14 2022-04-15 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. ANTIBODIES AGAINST CLAUDIN 18.2
CN117126279A (en) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 GIPR antibody and fusion protein of GIPR antibody and GLP-1, and pharmaceutical composition and application thereof
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
CN110357959B (en) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 GCGR antibody, fusion protein of GCGR antibody and GLP-1, and pharmaceutical composition and application of GCGR antibody and fusion protein
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
JP7431750B2 (en) 2018-04-30 2024-02-15 武田薬品工業株式会社 Cannabinoid receptor type 1 (CB1) binding protein and its use
KR20210005097A (en) 2018-04-30 2021-01-13 메디뮨 리미티드 Conjugates that target and remove aggregates
US20210171610A1 (en) 2018-05-02 2021-06-10 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
MX2020011828A (en) 2018-05-25 2021-02-09 Alector Llc Anti-sirpa antibodies and methods of use thereof.
CN110655577A (en) 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ antibody and fusion protein thereof with Elabela, and pharmaceutical composition and application thereof
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
EA202190094A1 (en) 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
JP2021529520A (en) 2018-06-29 2021-11-04 アレクトル エルエルシー Anti-SIRP-Beta 1 antibody and how to use it
CN112584859A (en) 2018-07-02 2021-03-30 美国安进公司 anti-STEAP 1 antigen binding proteins
ES2940311T3 (en) 2018-07-13 2023-05-05 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
MX2021001221A (en) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3.
KR20210042117A (en) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Antibody constructs against CLDN18.2 and CD3
MA53493A (en) 2018-08-31 2021-07-07 Alx Oncology Inc POLYPEPTIDES LURES
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
CN113365697A (en) 2018-09-25 2021-09-07 百进生物科技公司 anti-TLR9 agents and compositions and methods of making and using the same
CN112839957A (en) 2018-09-28 2021-05-25 协和麒麟株式会社 IL-36 antibodies and uses thereof
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
CN113597319A (en) 2019-01-04 2021-11-02 分解治疗有限责任公司 Treatment of xerosis with nuclease fusion proteins
CN116063520A (en) 2019-01-30 2023-05-05 真和制药有限公司 anti-GAL 3 antibodies and uses thereof
BR112021015068A2 (en) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited PROPHYLATIC TREATMENT METHODS USING RECOMBINANT VWF (RVWF)
US20220080053A1 (en) 2019-02-07 2022-03-17 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
CA3131705A1 (en) 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
BR112021019128A2 (en) 2019-04-09 2022-01-04 Abcuro Inc Killer cell lectin-like receptor (klrg1) member 1 subfamily depleting antibodies
US20220243197A1 (en) 2019-04-30 2022-08-04 Gigagen, Inc. Recombinant Polyclonal Proteins and Methods of Use Thereof
PE20220287A1 (en) 2019-05-09 2022-02-25 Boehringer Ingelheim Int ANTI-SEMA3A ANTIBODIES AND THEIR USES TO TREAT EYE DISEASES
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
TW202115112A (en) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 Anti-angpt2 antibodies
BR112021024997A2 (en) 2019-07-03 2022-01-25 Oxford Biotherapeutics Ltd Antibodies, polynucleotide, expression vector, host cell, pharmaceutical composition, methods and use
CN112239507A (en) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 Fusion protein of ETA antibody and TGF-beta Trap, and pharmaceutical composition and application thereof
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2022543259A (en) 2019-08-02 2022-10-11 オレガ・バイオテック Novel IL-17B antibody
CA3150441A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
MX2022002981A (en) 2019-09-10 2022-04-06 Amgen Inc Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity.
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
CN112521501A (en) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof
TW202126685A (en) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
PE20221271A1 (en) 2019-11-04 2022-09-01 Alector Llc SIGLEC-9 ECD FUSION MOLECULES AND METHODS OF USE THEREOF
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
WO2021110562A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
JP2023505169A (en) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Interferon-associated antigen binding protein for use in treating hepatitis B infection
AU2020396548A1 (en) 2019-12-05 2022-07-14 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-CD47 antibody in combination with a tumor targeting antibody
TW202136303A (en) 2019-12-13 2021-10-01 美商阿列克特有限責任公司 Anti-mertk antibodies and methods of use thereof
AU2020407208A1 (en) 2019-12-17 2022-06-02 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
WO2021144020A1 (en) 2020-01-15 2021-07-22 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4090681A1 (en) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4100048A1 (en) 2020-02-04 2022-12-14 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
US20230183377A1 (en) 2020-02-26 2023-06-15 Sorrento Therapeutics, Inc. Activatable antigen binding proteins with universal masking moieties
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
KR20230015997A (en) 2020-05-26 2023-01-31 베링거 인겔하임 인터내셔날 게엠베하 Anti-PD-1 antibody
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
EP4169949A1 (en) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
WO2021263166A1 (en) 2020-06-26 2021-12-30 Sorrento Therapeutics, Inc. Anti-pd1 antibodies and uses thereof
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
JP2023540732A (en) 2020-09-04 2023-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CEACAM5 antibodies and conjugates and uses thereof
WO2022061061A1 (en) 2020-09-21 2022-03-24 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of inflammatory conditions
US20230381293A1 (en) 2020-10-14 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Stabilized norovirus virus-like particles as vaccine immunogens
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
KR20230098334A (en) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Polypeptide constructs that selectively bind to CLDN6 and CD3
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
CN116323671A (en) 2020-11-06 2023-06-23 安进公司 Multi-targeting bispecific antigen binding molecules with increased selectivity
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
US20240059766A1 (en) 2020-12-16 2024-02-22 Voyager Therapeutics, Inc. Tau binding compounds
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
US11623949B2 (en) 2021-01-28 2023-04-11 Talem Therapeutics Llc Anti-spike glycoprotein antibodies and the therapeutic use thereof
WO2022170008A2 (en) 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
JP2024515165A (en) 2021-03-26 2024-04-05 アブクロ，インク． Anti-KLRG1 antibody
CN115141276A (en) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 Antibody capable of being specifically combined with human endothelin receptor and application thereof in treatment of diabetic nephropathy and chronic nephropathy
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
JP2024513376A (en) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド MAGEB2 binding construct
IL307672A (en) 2021-05-06 2023-12-01 Amgen Res Munich Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022254379A1 (en) 2021-06-04 2022-12-08 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022258720A1 (en) 2021-06-09 2022-12-15 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099682A1 (en) 2021-12-02 2023-06-08 Sanofi Ceacam5 adc–anti-pd1/pd-l1 combination therapy
WO2023099683A1 (en) 2021-12-02 2023-06-08 Sanofi Cea assay for patient selection in cancer therapy
TW202342515A (en) 2021-12-22 2023-11-01 瑞士商Ｃｄｒ生命股份有限公司 Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
TW202346354A (en) 2022-03-09 2023-12-01 德商馬克專利公司 Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023194333A1 (en) 2022-04-04 2023-10-12 Swiftpharma Bv Recombinant spider silk-reinforced collagen proteins produced in plants and the use thereof
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
CA1055932A (en) * 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin

Also Published As

Publication number Publication date
GB2055868A (en) 1981-03-11
FR2460674A1 (en) 1981-01-30
US4301144A (en) 1981-11-17
JPS6023084B2 (en) 1985-06-05
FR2460674B1 (en) 1983-06-24
GB2055868B (en) 1983-04-07
DE3026398A1 (en) 1981-03-26
JPS5612308A (en) 1981-02-06
DE3026398C2 (en) 1990-09-13

Similar Documents

Publication Publication Date Title
CA1146858A (en) Blood substitute containing modified hemoglobin
US4377512A (en) Oxygen carrier for blood substitute
US3925344A (en) Plasma protein substitute
US5585484A (en) Hemoglobin crosslinkers
CA1273294A (en) Production of a-a cross-linked hemoglobins in high yield
US4412989A (en) Oxygen carrier
US5478805A (en) Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
JPS6289630A (en) Hemoglobin-polyoxyalkylene conjugate and freeze-dried pharmaceutical thereof
CH629961A5 (en) METHOD FOR PRODUCING A WATER-SOLUBLE, POLYMERIZED, CROSS-LINKED HAEMOGLOBIN.
DE10031740A1 (en) Artificial oxygen carriers from cross-linked modified human or pig hemoglobin with improved properties, processes for their technically simple production from purified material in high yields, and their use
US20040023851A1 (en) Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin
US7144989B2 (en) Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
IL87708A (en) Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof
KR102238718B1 (en) Polyalkylene oxide valerate hemoglobin conjugates
US5248766A (en) Oxirane-modified hemoglobin based composition
MX2014011763A (en) Diaspirin crosslinked pegylated hemoglobin.
US20040014641A1 (en) Mammalion haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
CA2072081C (en) Polyhemoglobin stabilized by purine derivatives and glutathione
CA1222207A (en) Process for preparing globin from haemoglobin and globin obtained by this process
AU782407B2 (en) Hemoglobin-antioxidant conjugates
GB1576752A (en) Haemoglobin preparation
EP0481013B1 (en) A composition for removing or inactivating harmful components in blood or other extracellular body fluids
EP0496866A1 (en) Hemoglobin-oligomer based composition and method to make same.
US5804551A (en) Pretraumatic use of hemoglobin
SU660975A1 (en) 2-n-benzoylamidoheptylamino-4-oxy-sym triazinylgarose as sorbent for hydrophobic chromatography of glycosidases

Legal Events

Date Code Title Description
MKEX Expiry